Core One Labs Balance Sheet Health

Financial Health criteria checks 0/6

Insufficient data to determine the health of Core One Labs

Key information

n/a

Debt to equity ratio

n/a

Debt

Interest coverage ratio	n/a
Cash	n/a
Equity	n/a
Total liabilities	n/a
Total assets	n/a

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: Insufficient data to determine if CLAB.F's short term assets cover its short term liabilities.

Long Term Liabilities: Insufficient data to determine if CLAB.F's short term assets cover its long term liabilities.

Debt to Equity History and Analysis

Debt Level: Insufficient data to calculate CLAB.F's net debt to equity ratio to determine if it is satisfactory.

Reducing Debt: Insufficient data to determine if CLAB.F's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: Insufficient data to determine if CLAB.F's debt is well covered by operating cash flow.

Interest Coverage: Insufficient data to determine if CLAB.F's interest payments on its debt are well covered by EBIT.

Core One Labs Balance Sheet Health

Financial Health criteria checks 0/6

Key information

Recent financial health updates

Recent updates

Core One Labs Inc. announced that it expects to receive CAD 1.5 million in funding

Core One Labs' Akome Reveals Impressive Results for Its Psychedelic Bio- Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods

Core One Labs Inc. announced that it has received CAD 0.2 million in funding

Core One Labs Inc. announced that it has received CAD 0.2 million in funding

Core One Labs Inc. announced that it expects to receive CAD 1 million in funding

Core One Labs Inc. announced that it expects to receive CAD 1 million in funding

Core One's Akome Reveals Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease

Core One Labs Inc.'s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease

Core One Labs Inc. Announces Management Changes

Core One Labs Inc. (CNSX:COOL) acquired GMP Drug Inc. for CAD 3.5 million.

Core One Labs Inc., Annual General Meeting, Feb 08, 2023

Core One Labs Inc. Prepares for Commercial Production of API-Grade Psilocybin

Core One Labs Applauds New Study Supporting Psilocybin Psychedelic Drug Therapy May Help Treat Alcohol Addiction

Core One Labs Inc. Announces Resignation of Ryan Hoggan from its Board of Directors

Core One Labs Inc. (CNSX:COOL) acquired Awakened Biosciences Inc.

Core One Labs Inc. Expects Imminent Breakthrough to Produce NMT, Precursor to DMT

Core One Labs Applauds Health Canada’s Amendments to Special Access Program, Allowing Physicians to Request Patient Access to Psychedelic Treatments

Core One Labs Inc. (CNSX:COOL) acquired New Path Laboratories Inc. for CAD 3.4 million.

Core One Labs Inc. (CNSX:COOL) acquired Frontier Mycology Corp. for CAD 7.5 million.

Core One Labs Inc. (CNSX:COOL) completed the acquisition of Akome Biotech Ltd.

Core One Labs Inc. (CNSX:COOL) acquired Bluejay Mental Health Group Inc.

Core One Labs in Collaboration with KICT to Explore DMT Assisted Psychotherapy

Core One Labs Inc. and Vocan Biotechnologies Inc. Initiates First Strain Production for Biosynthetic Psilocybin

Core One Labs Inc. (CNSX:COOL) entered into a letter of intent to acquire Ketamine Infusion Centers of Texas, LLC for $0.2 million.

High Tower Capital, Inc. completed the acquisition of Certain Assets of Core One Labs Inc. (CNSX : COOL).

Core One Labs Announces Breakthrough in Solving Psilocybin Dosing Problems by Introducing Biosynthetic Psilocybin to Its Patented Thinstrip Delivery Method

Core One Labs Inc. Announces Board Changes

Core One Labs Inc. (CNSX:COOL) completed the acquisition of Vocan Biotechnologies Inc.

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Discover healthy companies